UreAB recombinant urease oral vaccine with mucosal adjuvant data

ORVX reported initial Phase II data in 24 patients with chronic gastritis due to H. pylori infection, demonstrating immune responses and reduction of infection in some vaccine recipients.

As presented at the International Workshop on Gastroduodenal Pathology in Copenhagen, the urease vaccine was given in doses of 20, 60 or 180 mg with heat-labile toxin of E. coli as the adjuvant. Adjuvant also was given alone, and so was a placebo, as controls. Oral administration was weekly for four weeks. ...